Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells $274,051.32 in Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) EVP Ryan Savitz sold 3,044 shares of the firm’s stock in a transaction dated Wednesday, November 11th. The shares were sold at an average price of $90.03, for a total value of $274,051.32. Following the completion of the transaction, the executive vice president owned 29,276 shares in the company, valued at approximately $2,635,718.28. This represents a 9.42% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Ryan Savitz also recently made the following trade(s):

• On Thursday, November 12th, Ryan Savitz sold 17,724 shares of Dianthus Therapeutics stock. The stock was sold at an average price of $90.56, for a total value of $1,605,085.44.
• On Monday, November 9th, Ryan Savitz sold 100,713 shares of Dianthus Therapeutics stock. The stock was sold at an average price of $90.54, for a total value of $9,118,555.02.
• On Tuesday, November 10th, Ryan Savitz sold 2,561 shares of Dianthus Therapeutics stock. The shares were sold at an average price of $90.14, for a total transaction of $230,848.54.

Dianthus Therapeutics Price Performance

Shares of NASDAQ DNTH traded up $3.18 during mid-day trading on Thursday, hitting $92.48. The company’s stock had a trading volume of 921,016 shares, compared to its average volume of 931,449. The stock has a market cap of $5.21 billion, a price-to-earnings ratio of -23.18 and a beta of 1.47. Dianthus Therapeutics, Inc. has a one year low of $34.29 and a one year high of $117.88. The company’s fifty day simple moving average is $89.05 and its 200-day simple moving average is $86.15.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings results on Wednesday, November 4th. The company reported ($0.81) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.94) by $0.13. Dianthus Therapeutics had a negative net margin of 7,436.50% and a negative return on equity of 19.68%. The business had revenue of $1.21 million during the quarter, compared to the consensus estimate of $0.46 million. On average, sell-side analysts predict that Dianthus Therapeutics, Inc. will post -3.55 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in DNTH. EFG International AG acquired a new stake in shares of Dianthus Therapeutics during the second quarter worth $49,000. GAMMA Investing LLC boosted its position in Dianthus Therapeutics by 83.6% during the third quarter. GAMMA Investing LLC now owns 558 shares of the company’s stock valued at $49,000 after purchasing an additional 254 shares during the last quarter. Fifth Third Bancorp grew its stake in Dianthus Therapeutics by 23.6% in the third quarter. Fifth Third Bancorp now owns 676 shares of the company’s stock valued at $60,000 after purchasing an additional 129 shares in the last quarter. Global Retirement Partners LLC bought a new position in Dianthus Therapeutics in the second quarter valued at approximately $93,000. Finally, Nisa Investment Advisors LLC increased its position in shares of Dianthus Therapeutics by 75.0% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,057 shares of the company’s stock worth $93,000 after purchasing an additional 453 shares during the last quarter. 47.53% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have commented on DNTH shares. Raymond James Financial reaffirmed a “strong-buy” rating and set a $134.00 target price on shares of Dianthus Therapeutics in a report on Thursday, November 5th. Citigroup assumed coverage on Dianthus Therapeutics in a research report on Friday, September 4th. They issued a “buy” rating and a $156.00 price target on the stock. Wedbush raised their price target on Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 5th. Roth Capital assumed coverage on Dianthus Therapeutics in a research note on Tuesday, October 27th. They set a “buy” rating and a $113.00 price objective for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $158.00 price objective on shares of Dianthus Therapeutics in a report on Thursday, October 15th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Dianthus Therapeutics currently has an average rating of “Buy” and a consensus price target of $128.77.

About Dianthus Therapeutics

Dianthus Therapeutics is a clinical-stage biotechnology company developing medicines for autoimmune and inflammatory diseases involving the complement system, a part of the immune system. The company’s research focuses on selectively targeting complement activity that contributes to disease. Dianthus became a publicly traded company in 2023 through a merger with Magenta Therapeutics. Its clinical development activities are intended to support potential use across patient populations, though the company has not established a commercial geographic footprint.